Optical coupling structure and optical transreceiver module
    41.
    发明授权
    Optical coupling structure and optical transreceiver module 有权
    光耦合结构和光收发模块

    公开(公告)号:US08909010B2

    公开(公告)日:2014-12-09

    申请号:US13542241

    申请日:2012-07-05

    摘要: Provided is an optical coupling structure including an optical semiconductor element including a light receiving/emitting portion, an optical transmission path having an optical axis that intersects the optical axis of the optical semiconductor element at a predetermined angle, and an optical coupling portion configured to convert the optical path between the optical semiconductor element and the optical transmission path and optically couple them. The optical coupling portion is made of a resin that is transparent with respect to a transmitted light, the resin adhering to both at least a portion of the light receiving/emitting portion and at least a portion of the end portion of the optical transmission path, and the optical semiconductor element and the optical transmission path are bonded to each other with the resin itself that constitutes the optical coupling portion.

    摘要翻译: 提供一种光耦合结构,其包括光学半导体元件,该光学半导体元件包括光接收/发射部分,具有与光学半导体元件的光轴以预定角度相交的光轴的光传输路径和被配置为转换 光学半导体元件和光学传输路径之间的光路并且光学耦合它们。 光耦合部分由相对于透射光透明的树脂制成,树脂粘附在光接收/发射部分的至少一部分和光传输路径的端部的至少一部分上, 并且光学半导体元件和光传输路径通过构成光耦合部分的树脂本身彼此接合。

    Semiconductor memory system
    42.
    发明授权

    公开(公告)号:US08804393B2

    公开(公告)日:2014-08-12

    申请号:US13418619

    申请日:2012-03-13

    IPC分类号: G11C5/02

    摘要: According to one embodiment, a semiconductor memory system includes a substrate, a plurality of elements and an adhesive portion. The substrate has a multilayer structure in which wiring patterns are formed, and has a substantially rectangle shape in a planar view. The elements are provided and arranged along the long-side direction of a surface layer side of the substrate. The adhesive portion is filled in a gap between the elements and in a gap between the elements and the substrate, where surfaces of the elements are exposed.

    ANTI-ICAM3 ANTIBODY AND USE THEREOF
    45.
    发明申请
    ANTI-ICAM3 ANTIBODY AND USE THEREOF 审中-公开
    抗ICAM3抗体及其用途

    公开(公告)号:US20120321557A1

    公开(公告)日:2012-12-20

    申请号:US13581175

    申请日:2011-02-25

    申请人: Naoki Kimura

    发明人: Naoki Kimura

    摘要: Based on an anti-ICAM3 antibody obtained by immunizing a mouse with BaF3 cells having artificially over-expressed ICAM3, a chimeric antibody has been successfully prepared which exerts cytotoxic actions, including both a proliferation-suppressing activity and an ADCC activity, on a blood cancer cell line, and which exerts a tumor regression activity in vivo.

    摘要翻译: 基于通过用具有人源超表达的ICAM3的BaF3细胞免疫小鼠获得的抗ICAM3抗体,已经成功制备了对血液癌发挥细胞毒作用,包括增殖抑制活性和ADCC活性的嵌合抗体 细胞系,并在体内发挥肿瘤的回归活性。

    ANTIBODY CAPABLE OF RECOGNIZING HLA CLASS I
    46.
    发明申请
    ANTIBODY CAPABLE OF RECOGNIZING HLA CLASS I 审中-公开
    抗体鉴定能力的抗体I

    公开(公告)号:US20120244142A1

    公开(公告)日:2012-09-27

    申请号:US13497545

    申请日:2010-09-24

    摘要: An objective of the present invention is to provide antibodies that recognize HLA class I and have significant cell death-inducing activity. To achieve the above objective, first, the present inventors immunized mice with soluble HLA-A to which a FLAG tag is attached. Four days after the final immunization, spleen cells from the mice were fused with mouse myeloma cells. Then, hybridoma screening was carried out using the cell aggregation-inducing activity and cell death-inducing activity as an index. Thus, the monoclonal antibody F17B1 that has strong cell death-inducing activity was selected. The sequences of the H chain and L chain variable regions of the mouse monoclonal antibody F17B1 were determined to humanize this antibody. Then, the humanized anti-HLA class I antibody H2-G1d_L1-k0 was assessed for cell death induction. The result showed that H2-G1d_L1-k0 suppressed the growth of the IM9 cell line in a concentration dependent manner.

    摘要翻译: 本发明的目的是提供识别HLA I类并具有显着的细胞死亡诱导活性的抗体。 为了实现上述目的,首先,本发明人用附着有FLAG标签的可溶性HLA-A免疫小鼠。 最后免疫4天后,将来自小鼠的脾细胞与小鼠骨髓瘤细胞融合。 然后,使用细胞聚集诱导活性和细胞死亡诱导活性作为指标进行杂交瘤筛选。 因此,选择具有强细胞死亡诱导活性的单克隆抗体F17B1。 确定小鼠单克隆抗体F17B1的H链和L链可变区的序列以使该抗体人源化。 然后,评估人源化抗HLA I类抗体H2-G1d_L1-k0的细胞死亡诱导。 结果表明,H2-G1d_L1-k0以浓度依赖性方式抑制IM9细胞系的生长。

    YS68 GENE INVOLVED IN PRIMITIVE HEMATOPOIESIS
    47.
    发明申请
    YS68 GENE INVOLVED IN PRIMITIVE HEMATOPOIESIS 失效
    涉及原发性HEMATOPOIESIS的YS68基因

    公开(公告)号:US20100304401A1

    公开(公告)日:2010-12-02

    申请号:US12837241

    申请日:2010-07-15

    IPC分类号: G01N33/53 C07K14/00 C07K16/00

    CPC分类号: C07K14/47 A61K38/00

    摘要: A novel gene, dubbed “YS68”, involved in primitive hematopoiesis was successfully isolated from cDNA derived from mouse yolk sacs. In addition, a human gene corresponding to this gene was successfully isolated. Expression characteristics of these genes suggested their involvement in primitive hematopoiesis. The proteins of this invention and genes encoding the proteins may be utilized as tools for drug development against diseases, such as hematological disorders.

    摘要翻译: 从源自小鼠卵黄囊的cDNA中成功分离了一种称为“YS68”的新基因,涉及原始造血。 此外,成功分离了与该基因相对应的人类基因。 这些基因的表达特征表明它们参与原始造血。 本发明的蛋白质和编码蛋白质的基因可以用作针对疾病如血液学疾病的药物开发的工具。

    ANTI-CANCER AGENT COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT
    48.
    发明申请
    ANTI-CANCER AGENT COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT 有权
    将抗HB-EGF抗体作为活性成分包含的抗癌药物

    公开(公告)号:US20100273988A1

    公开(公告)日:2010-10-28

    申请号:US12311950

    申请日:2007-10-19

    申请人: Naoki Kimura

    发明人: Naoki Kimura

    IPC分类号: C07K16/46 C07K16/22 C07K16/00

    摘要: A monoclonal antibody having a neutralizing activity on HB-EGF is disclosed. The monoclonal antibody of the present invention is preferably an antibody that does not bind to the HB-EGF protein on the cell surface of HB-EGF-expressing cells. Also provided are an anti-cancer agent and a cell proliferation inhibitor, which comprise the monoclonal antibody of the present invention as an active ingredient, and a method of treating cancer, the method comprising administering the monoclonal antibody of the present invention. Cancers that can be treated by the anti-cancer agent of the present invention include pancreatic cancer, liver cancer, esophageal cancer, melanoma, colorectal cancer, gastric cancer, ovarian cancer, bladder cancer, and brain tumors.

    摘要翻译: 公开了具有HB-EGF中和活性的单克隆抗体。 本发明的单克隆抗体优选为在HB-EGF表达细胞的细胞表面不结合HB-EGF蛋白的抗体。 还提供了包含本发明的单克隆抗体作为活性成分的抗癌剂和细胞增殖抑制剂以及治疗癌症的方法,所述方法包括施用本发明的单克隆抗体。 可以通过本发明的抗癌剂治疗的癌症包括胰腺癌,肝癌,食管癌,黑素瘤,结肠直肠癌,胃癌,卵巢癌,膀胱癌和脑肿瘤。

    OPTICAL DISK DEVICE AND POWER SUPPLY METHOD
    49.
    发明申请
    OPTICAL DISK DEVICE AND POWER SUPPLY METHOD 审中-公开
    光盘设备和电源方法

    公开(公告)号:US20090245050A1

    公开(公告)日:2009-10-01

    申请号:US12415608

    申请日:2009-03-31

    IPC分类号: G11B7/12

    摘要: According to one embodiment, an optical disk device includes types of semiconductor laser diodes configured to emit laser light of different wavelengths, an output control circuit configured to control light output of each semiconductor laser diode, and a composite power source configured to generate voltages required for driving the types of semiconductor laser diodes and operating the output control circuit from a single power source voltage and to selectively output the generated voltages. The composite power source includes an input port to input an external control signal at a time of voltage selection and is configured to change the output voltage stepwise in response to the control signal.

    摘要翻译: 根据一个实施例,光盘装置包括配置为发射不同波长的激光的半导体激光二极管的类型,被配置为控制每个半导体激光二极管的光输出的输出控制电路和被配置为产生 驱动类型的半导体激光二极管,并从单个电源电压操作输出控制电路并选择性地输出所产生的电压。 复合电源包括在电压选择时输入外部控制信号的输入端口,并且被配置为响应于控制信号逐步改变输出电压。